While some targets are chosen because of their functional relevance to AML pathogenesis (CD5, CD33, CD36), others are of particular interest due to their relatively upregulated expression on AML cells or potency in pre-clinical trials (CD44, CD64, CD123). The gene discussed is FCGR1A; the disease is acute myeloid leukemia.